Adamas Pharmaceuticals Announces Closing of Public Offering of Common Stock & Full Exercise of Underwriters’ Option to Purc...
March 01 2021 - 4:04PM
Business Wire
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated
to developing and delivering medicines that make a meaningful
difference to people affected by neurological diseases, today
announced the closing of its previously announced underwritten
public offering of 12,500,000 shares of its common stock, plus the
exercise in full by the underwriters of their option to purchase an
additional 1,875,000 shares, at a price to the public of $4.40 per
share. The estimated net proceeds of the offering to Adamas, after
deducting underwriting discounts and commissions and other offering
expenses, are expected to be $59.2 million.
SVB Leerink and William Blair acted as joint bookrunning
managers for the offering. JMP Securities acted as lead manager for
the offering.
The securities described above were offered by Adamas pursuant
to a shelf registration statement previously filed with and
declared effective by the Securities and Exchange Commission (the
"SEC"). The final prospectus supplement and accompanying prospectus
related to this offering were filed with the SEC and are available
on the SEC's website at www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to this
offering may be obtained, from: SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808 7525, ext. 6105, or by email at
syndicate@svbleerink.com; or William Blair & Company, L.L.C.,
Attention: Prospectus Department, 150 North Riverside Plaza,
Chicago, IL 60606, telephone: 1-800-621-0687, or by email:
prospectus@williamblair.com.
About Adamas
At Adamas our vision is clear – to deliver innovative medicines
that reduce the burden of neurological diseases on patients,
caregivers and society. We are a fully integrated company focused
on growing a portfolio of therapies to address a range of
neurological diseases.
Source: Adamas Pharmaceuticals, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210301005925/en/
Media: Sarah Mathieson Vice President, Corporate
Communications 510-450-3528 smathieson@adamaspharma.com
Investors: Peter Vozzo Managing Director Westwicke/ICR
443-213-0505 peter.vozzo@westwicke.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024